NASDAQ:INBX Inhibrx (INBX) Stock Price, News & Analysis → Claim Your Complimentary Bitcoin Reward (From Crypto Swap Profits) (Ad) Free INBX Stock Alerts $34.94 -0.06 (-0.17%) (As of 03/18/2024 ET) Add Compare Share Share Today's Range$34.90▼$35.2250-Day Range$32.76▼$39.5652-Week Range$14.31▼$39.79Volume539,707 shsAverage Volume627,826 shsMarket Capitalization$1.66 billionP/E RatioN/ADividend YieldN/APrice Target$27.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Inhibrx alerts: Email Address Inhibrx MarketRank™ Stock AnalysisAnalyst RatingHold2.00 Rating ScoreUpside/Downside22.7% Downside$27.00 Price TargetShort InterestHealthy5.48% of Float Sold ShortDividend StrengthN/ASustainability-1.21Upright™ Environmental ScoreNews Sentiment0.78Based on 5 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.95 out of 5 starsMedical Sector476th out of 946 stocksBiological Products, Except Diagnostic Industry80th out of 160 stocks 1.0 Analyst's Opinion Consensus RatingInhibrx has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $27.00, Inhibrx has a forecasted downside of 22.7% from its current price of $34.94.Amount of Analyst CoverageInhibrx has only been the subject of 2 research reports in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted5.48% of the float of Inhibrx has been sold short.Short Interest Ratio / Days to CoverInhibrx has a short interest ratio ("days to cover") of 2.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Inhibrx has recently decreased by 7.14%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldInhibrx does not currently pay a dividend.Dividend GrowthInhibrx does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreInhibrx has received a 71.13% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for cancer", "Clinical research services for deficiency diseases", and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Inhibrx is -1.21. Previous Next 2.7 News and Social Media Coverage News SentimentInhibrx has a news sentiment score of 0.78. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Inhibrx this week, compared to 1 article on an average week.Search InterestOnly 1 people have searched for INBX on MarketBeat in the last 30 days. This is a decrease of -80% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Inhibrx to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Inhibrx insiders have not sold or bought any company stock.Percentage Held by Insiders25.80% of the stock of Inhibrx is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions82.46% of the stock of Inhibrx is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Inhibrx is -6.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Inhibrx is -6.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioInhibrx has a P/B Ratio of 37.98. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Banyan Hill PublishingAI Cracks Open Largest Untapped Energy Reserve on EarthThis orb represents the largest untapped energy source in the world… And although this energy resource is unknown by 99% of the public… It makes gas, coal, oil, wind, hydropower, solar, fusion… ]click here to watch a free presentation where I reveal all the details of this lucrative opportunit About Inhibrx Stock (NASDAQ:INBX)Inhibrx, Inc., a clinical-stage biopharmaceutical company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcinoma; INBRX-105, a tetravalent conditional agonist of programmed death-ligand 1 and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with locally advanced or metastatic solid tumors; and INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also develops INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company has collaboration with 2seventy bio, Inc., Bristol-Myers Squibb Company, and Chiesi Farmaceutici S.p.A. The company was founded in 2010 and is headquartered in La Jolla, California.Read More INBX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart INBX Stock News HeadlinesMarch 16, 2024 | finance.yahoo.comINBX Apr 2024 50.000 putMarch 16, 2024 | finance.yahoo.comINBX Apr 2024 55.000 callMarch 19, 2024 | Colonial Metals (Ad)Central Bank Gold Heist In ProgressWhen central banks buy gold… The rich buy right along with them. And central banks are buying at breakneck pace. Last year… 1,037 tons. Just 45 tons less than the record set two years ago.March 13, 2024 | americanbankingnews.comHead-To-Head Review: Novavax (NASDAQ:NVAX) and Inhibrx (NASDAQ:INBX)February 29, 2024 | realmoney.thestreet.comInhibrx just downgraded at Jefferies, here's whyFebruary 28, 2024 | finanznachrichten.deInhibrx, Inc.: Inhibrx Reports Fourth Quarter and Fiscal Year 2023 Financial ResultsFebruary 28, 2024 | prnewswire.comInhibrx Reports Fourth Quarter and Fiscal Year 2023 Financial ResultsFebruary 10, 2024 | businesswire.comINHIBRX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Inhibrx, Inc. - INBXMarch 19, 2024 | Porter & Company (Ad)The world’s greatest investmentI believe this could change your life forever. I’m talking about transforming everything for you, financially. You see, a rare market anomaly has emerged that I believe is going to make some people very wealthy. Almost nobody in the mainstream media or Wall Street has connected the dots on what’s going on, but that ignorance won’t last for long. When they wake up to this situation, billions of dollars will flood in.February 10, 2024 | businesswire.comINHIBRX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Inhibrx, Inc. - INBXJanuary 24, 2024 | msn.comSanofi signs agreement to acquire Inhibrx for $1.7bnJanuary 24, 2024 | finance.yahoo.comBiotech Stock Roundup: GILD Down on Study Results, INBX Gains on Sanofi Deal & MoreJanuary 24, 2024 | seekingalpha.comSanofi Expands Rare Disease Focus With Inhibrx's INBRX-101 AcquisitionJanuary 24, 2024 | finance.yahoo.comInhibrx, Inc. (INBX) Soars 8.9%: Is Further Upside Left in the Stock?January 24, 2024 | realmoney.thestreet.comInhibrx just downgraded at LifeSci Capital, here's whyJanuary 23, 2024 | msn.comThese Stocks Are Moving the Most Today: United, Logitech, Archer Daniels, Inhibrx, J&J, Netflix, and MoreJanuary 23, 2024 | marketwatch.comSanofi to Buy Assets From Inhibrx in Deal Valued at Up to $2.2 Billion -- UpdateJanuary 23, 2024 | reuters.comFrance's Sanofi to buy U.S. drugs project INBRX-101 for about $2.2 blnJanuary 23, 2024 | tmcnet.comINBX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Inhibrx, Inc. Is Fair to ShareholdersDecember 9, 2023 | morningstar.comInhibrx Inc Ordinary Shares INBXDecember 2, 2023 | morningstar.comInhibrx Inc Ordinary SharesNovember 10, 2023 | msn.comInhibrx posts Q3 resultsNovember 10, 2023 | finanznachrichten.deInhibrx, Inc.: Inhibrx Reports Third Quarter 2023 Financial Results and Recent Corporate HighlightsNovember 9, 2023 | finance.yahoo.comInhibrx Reports Third Quarter 2023 Financial Results and Recent Corporate HighlightsNovember 4, 2023 | msn.comInhibrx reports initial Phase I Ewing sarcoma trial dataNovember 2, 2023 | finance.yahoo.comInhibrx Announces Preliminary Data from the Phase 1 Trial of INBRX-109 for the Treatment of Ewing SarcomaSeptember 19, 2023 | finance.yahoo.comInhibrx Retains Rights to INBRX-101 for the Treatment of Alpha-1 Antitrypsin Deficiency Outside of the United States and CanadaSee More Headlines Receive INBX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Inhibrx and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/28/2024Today3/18/2024Next Earnings (Estimated)5/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:INBX CUSIPN/A CIK1739614 Webwww.inhibrx.com Phone858-795-4220FaxN/AEmployees132Year FoundedN/APrice Target and Rating Average Stock Price Target$27.00 High Stock Price Target$27.00 Low Stock Price Target$27.00 Potential Upside/Downside-22.7%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($5.03) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-241,360,000.00 Net Margins-13,408.95% Pretax Margin-13,318.00% Return on Equity-590.78% Return on Assets-84.13% Debt Debt-to-Equity Ratio4.78 Current Ratio5.24 Quick Ratio5.25 Sales & Book Value Annual Sales$1.80 million Price / Sales919.89 Cash FlowN/A Price / Cash FlowN/A Book Value$0.92 per share Price / Book37.98Miscellaneous Outstanding Shares47,390,000Free Float36,871,000Market Cap$1.66 billion OptionableOptionable Beta2.94 Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report Key ExecutivesMr. Mark Paul Lappe (Age 57)Founder, Chairman, President & CEO Comp: $1.02MDr. Brendan P. Eckelman Ph.D. (Age 45)Founder & Chief Scientific Officer Comp: $704kMs. Kelly Devine Deck B.S. (Age 43)CPA, M.S., Executive VP & CFO Comp: $531.17kMr. Quinn L. DeverauxFounderDr. Ashraf Amanullah (Age 56)Executive VP & Chief Technical Operations Officer Ms. Leah Pollema J.D.VP, Corporate Secretary & General CounselDr. Charbel Helaihel Pharm.D.Vice President of Marketing & Commercial PlanningMr. Jeffrey J. JensenExecutive VP & Chief Clinical Operations OfficerMr. David Matly M.B.A.Executive VP and Chief Commercial & Business Development OfficerDr. Carlos Bais Ph.D.Executive Vice President of Translational SciencesMore ExecutivesKey CompetitorsAmbrx BiopharmaNYSE:AMAMAdaptimmune TherapeuticsNASDAQ:ADAP4D Molecular TherapeuticsNASDAQ:FDMTADMA BiologicsNASDAQ:ADMATwist BioscienceNASDAQ:TWSTView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Bought 84,512 shares on 3/11/2024Ownership: 3.955%Wellington Management Group LLPSold 29,501 shares on 3/5/2024Ownership: 0.307%Readystate Asset Management LPBought 13,839 shares on 2/20/2024Ownership: 0.029%Quarry LPBought 750 shares on 2/20/2024Ownership: 0.002%Price T Rowe Associates Inc. MDBought 986 shares on 2/16/2024Ownership: 0.029%View All Insider TransactionsView All Institutional Transactions INBX Stock Analysis - Frequently Asked Questions Should I buy or sell Inhibrx stock right now? 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Inhibrx in the last year. There are currently 2 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" INBX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in INBX, but not buy additional shares or sell existing shares. View INBX analyst ratings or view top-rated stocks. What is Inhibrx's stock price target for 2024? 2 analysts have issued 12 month price objectives for Inhibrx's stock. Their INBX share price targets range from $27.00 to $27.00. On average, they predict the company's stock price to reach $27.00 in the next year. This suggests that the stock has a possible downside of 22.7%. View analysts price targets for INBX or view top-rated stocks among Wall Street analysts. How have INBX shares performed in 2024? Inhibrx's stock was trading at $38.00 on January 1st, 2024. Since then, INBX stock has decreased by 8.1% and is now trading at $34.94. View the best growth stocks for 2024 here. Are investors shorting Inhibrx? Inhibrx saw a decline in short interest in the month of February. As of February 29th, there was short interest totaling 1,950,000 shares, a decline of 7.1% from the February 14th total of 2,100,000 shares. Based on an average daily trading volume, of 747,100 shares, the short-interest ratio is presently 2.6 days. Approximately 5.5% of the shares of the company are short sold. View Inhibrx's Short Interest. When is Inhibrx's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024. View our INBX earnings forecast. How were Inhibrx's earnings last quarter? Inhibrx, Inc. (NASDAQ:INBX) announced its quarterly earnings results on Wednesday, February, 28th. The company reported ($1.73) EPS for the quarter, missing the consensus estimate of ($1.07) by $0.66. The firm earned $1.63 million during the quarter, compared to analyst estimates of $0.10 million. Inhibrx had a negative net margin of 13,408.95% and a negative trailing twelve-month return on equity of 590.78%. What other stocks do shareholders of Inhibrx own? Based on aggregate information from My MarketBeat watchlists, some companies that other Inhibrx investors own include Advanced Micro Devices (AMD), Trevena (TRVN), Vivint Solar (VSLR), Activision Blizzard (ATVI), Daqo New Energy (DQ), Fastly (FSLY), Innovative Industrial Properties (IIPR), Lovesac (LOVE) and Micron Technology (MU). When did Inhibrx IPO? (INBX) raised $102 million in an initial public offering on Wednesday, August 19th 2020. The company issued 6,000,000 shares at $16.00-$18.00 per share. Jefferies, Evercore ISI and Credit Suisse served as the underwriters for the IPO and LifeSci Capital was co-manager. Who are Inhibrx's major shareholders? Inhibrx's stock is owned by a variety of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (3.96%), Vanguard Group Inc. (3.96%), Vestal Point Capital LP (3.24%), Capital Research Global Investors (1.51%), PFM Health Sciences LP (1.14%) and Russell Investments Group Ltd. (0.92%). Insiders that own company stock include Brendan P Eckelman, Global Investors Lp Viking, Jon Faiz Kayyem and Mark Lappe. View institutional ownership trends. How do I buy shares of Inhibrx? Shares of INBX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:INBX) was last updated on 3/19/2024 by MarketBeat.com Staff From Our PartnersCentral Bank Gold Heist In ProgressColonial Metals8,788% Return Predicted For THIS Crypto (already up 40% in 6 months)Paradigm PressLike Tiny Crypto Retirement FundsCrypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceThe world’s greatest investmentPorter & CompanySHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceBitcoin dollar warningStansberry ResearchThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Inhibrx, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.